Based on the Charles River Laboratories stock forecast from 11 analysts, the average analyst target price for Charles River Laboratories is USD 219.55 over the next 12 months. Charles River Laboratories’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Charles River Laboratories is Slightly Bullish , which is based on 8 positive signals and 4 negative signals. At the last closing, Charles River Laboratories’s stock price was USD 187.74. Charles River Laboratories’s stock price has changed by -12.84% over the past week, -3.16% over the past month and +0.09% over the last year.
No recent analyst target price found for Charles River Laboratories
No recent average analyst rating found for Charles River Laboratories
Company Overview Charles River Laboratories
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts. Read Less
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Disco...Read More
Frequently Asked Questions About Charles River Laboratories (CRL) Stock
Based on ratings from 11 analysts Charles River Laboratories's stock is Buy . Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 5 buy, 1 sell and 12 hold ratings.
Unfortunately we do not have enough data on CRL's stock to indicate if its a good dividend stock.
Based on targets from 11 analysts, the average taret price for CRL is USD 219.55 over the next 12 months. The maximum analyst target price is USD 290 while the minimum anlayst target price is USD 175.
CRL stock's Price/Earning ratio is 21.65.
Our analysis grades CRL stock's Price / Earning ratio at B+. This means that CRL stock's Price/Earning ratio is above 12% of the stocks in the Diagnostics & Research sector in the NYE exchange.
Based on this CRL may be undervalued for its sector.
The last closing price of CRL's stock was USD 187.74.
The most recent market capitalization for CRL is USD 9.42B.
Based on targets from 11 analysts, the average taret price for CRL is projected at USD 219.55 over the next 12 months.
This means that CRL's stock price may go up by +16.94% over the next 12 months.
We can't find any ETFs which contains Charles River Laboratories's stock.
As per our most recent records Charles River Laboratories has 20,400 Employees.
Charles River Laboratories's registered address is 251 Ballardvale Street, Wilmington, MA, United States, 01887.
You can get more information about it from Charles River Laboratories's website at https://www.criver.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced on cashflow basis
The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Underpriced on free cash flow basis
The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
What not to like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Frequently Asked Questions About Charles River Laboratories (CRL) Stock
Based on ratings from 11 analysts Charles River Laboratories's stock is Buy . Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 5 buy, 1 sell and 12 hold ratings.
Unfortunately we do not have enough data on CRL's stock to indicate if its a good dividend stock.
Based on targets from 11 analysts, the average taret price for CRL is USD 219.55 over the next 12 months. The maximum analyst target price is USD 290 while the minimum anlayst target price is USD 175.
CRL stock's Price/Earning ratio is 21.65.
Our analysis grades CRL stock's Price / Earning ratio at B+. This means that CRL stock's Price/Earning ratio is above 12% of the stocks in the Diagnostics & Research sector in the NYE exchange.
Based on this CRL may be undervalued for its sector.
The last closing price of CRL's stock was USD 187.74.
The most recent market capitalization for CRL is USD 9.42B.
Based on targets from 11 analysts, the average taret price for CRL is projected at USD 219.55 over the next 12 months.
This means that CRL's stock price may go up by +16.94% over the next 12 months.
We can't find any ETFs which contains Charles River Laboratories's stock.
As per our most recent records Charles River Laboratories has 20,400 Employees.
Charles River Laboratories's registered address is 251 Ballardvale Street, Wilmington, MA, United States, 01887.
You can get more information about it from Charles River Laboratories's website at https://www.criver.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for CRL !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
